Rapport Therapeutics, Inc.
RAPP· Nasdaq
Released Mar 10, 2026, before the open
10-K filed Mar 10, 2026, 69 days after period end · 0001193125-26-099360
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|---|
| Net Income | -$33.76M | -$19.98M | -$13.52M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rapport Therapeutics, Inc. · CIK 2012593 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 10, 2026 · 69 d after period end
2.9% from the close of Mar 9, 2026 to the close of Mar 10, 2026, the first after the release.